aaiPharma Inc. announced that it has received approval of a new methadone label from the US Food and Drug Administration for its parenterally administered methadone product (formerly branded as Dolophine Injection).

"Methadone hydrochloride injection is an important product for patients in moderate to severe pain requiring intrathecal, intravenous, subcutaneous or intramuscular treatment," commented Dr Philip Tabbiner, CEO of aaiPharma. "We are pleased with the collaborative effort with the FDA that led to the labeling we received and are ready to meet the patient need for this medically necessary pain management treatment."

aaiPharma offers physicians and patients one of the most comprehensive portfolios of pain products. Currently, the company markets the Darvon and Darvocet A500 family of pain management products for the treatment of mild-to-moderate pain, and is developing a pipeline of line extensions to this brand franchise as well as novel products for the treatment of pain. These products, coupled with the recently acquired Oramorph SR, Roxicodone, Roxanol and Duraclon products, will provide physicians with treatment options across a broad spectrum of prescription pain relief.